Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Examples of biology informing treatment decisions in CLL

Kostas Stamatopoulos • 9 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Ibrutinib

Kostas Stamatopoulos, MD, PhD, of the Center for Research and Technology Hellas, Thermi, Greece, discusses how a greater understanding of disease biology can inform treatment decisions in chronic lymphocytic leukemia (CLL), including ribosomal profiling of patients treated with ibrutinib as well as the significance of aberrant p53 signalling in CLL. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Kostas Stamatopoulos

3:19
Translating scientific advances into clinical success in CLL: satellite symposium highlights
Kostas Stamatopoulos • 19 Mar 2022
2:02
The link between the tumor microenvironment & gene expression in CLL
Kostas Stamatopoulos • 19 Mar 2022
1:46
Pathogenesis and transformation in CLL: session highlights
Kostas Stamatopoulos • 19 Mar 2022
2:54
The definition of high-risk CLL
Kostas Stamatopoulos • 19 Mar 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals